2021
DOI: 10.1093/bioinformatics/btab340
|View full text |Cite
|
Sign up to set email alerts
|

CLEP: a hybrid data- and knowledge-driven framework for generating patient representations

Abstract: As machine learning and artificial intelligence increasingly attain a larger number of applications in the biomedical domain, at their core, their utility depends on the data used to train them. Due to the complexity and high dimensionality of biomedical data, there is a need for approaches that combine prior knowledge around known biological interactions with patient data. Here, we present CLEP, a novel approach that generates new patient representations by leveraging both prior knowledge and patient-level da… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5
2
1

Relationship

2
6

Authors

Journals

citations
Cited by 8 publications
(7 citation statements)
references
References 46 publications
0
7
0
Order By: Relevance
“…The complexity and dimensionality of biomedical data require methodologies that integrate existing biological knowledge with patient-specific data, such as knowledge graphs [ 13 , 14 ]. For example, CLinical Embedding of Patients (CLEP) [ 15 ] incorporates patient-level multi-omics data into a knowledge graph to model the underlying relationships between patients and clinical features for identifying Alzheimer’s patients and their properties. Medical knowledge graphs or deep architectures that utilize patient-level medical data are important for developing accurate and generalizable clinical decision-support models [ 15 – 22 ].…”
Section: Related Workmentioning
confidence: 99%
See 1 more Smart Citation
“…The complexity and dimensionality of biomedical data require methodologies that integrate existing biological knowledge with patient-specific data, such as knowledge graphs [ 13 , 14 ]. For example, CLinical Embedding of Patients (CLEP) [ 15 ] incorporates patient-level multi-omics data into a knowledge graph to model the underlying relationships between patients and clinical features for identifying Alzheimer’s patients and their properties. Medical knowledge graphs or deep architectures that utilize patient-level medical data are important for developing accurate and generalizable clinical decision-support models [ 15 – 22 ].…”
Section: Related Workmentioning
confidence: 99%
“…For example, CLinical Embedding of Patients (CLEP) [ 15 ] incorporates patient-level multi-omics data into a knowledge graph to model the underlying relationships between patients and clinical features for identifying Alzheimer’s patients and their properties. Medical knowledge graphs or deep architectures that utilize patient-level medical data are important for developing accurate and generalizable clinical decision-support models [ 15 – 22 ]. Moreover, the utilization of a personalized biomedical graph enables the identification of patient-specific biological mechanisms [ 7 , 15 , 23 , 24 ], offering further insights into the causal relationships in specific diseases or patient subgroups.…”
Section: Related Workmentioning
confidence: 99%
“…The evolution of multi-modal knowledge graph research has initially revolved around two predominant modes: images and text [23,25]. Literature[26] laid the foundation by de ning multi-modal knowledge graphs, beginning with tasks such as link prediction and ontology matching.…”
Section: Advances In Multimodal Knowledge Graphmentioning
confidence: 99%
“…While homogeneous networks, such as protein-protein interaction networks, can represent relationships between a single entity type, knowledge graphs (KGs) can incorporate a broad range of biological scales, from the genetic and molecular level (e.g., proteins, drugs, and biochemicals), to biological concepts (e.g., phenotypes and diseases). These KGs can then be utilized for several applications in drug discovery, such as providing insights into molecular mechanisms and therapeutic targets [ 1 2 ], side effect prediction in the early stages of drug development [ 3 ], target prioritization [ 4 ], and drug repositioning [ 5 ].…”
Section: Introductionmentioning
confidence: 99%